Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Lakartidningen - 105(2008), 32-33 vom: 01. Aug., Seite 2181-4 |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor |
|---|
| Beteiligte Personen: |
Fernö, Mårten [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 15.09.2008 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM182322696 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM182322696 | ||
| 003 | DE-627 | ||
| 005 | 20231223162706.0 | ||
| 007 | tu | ||
| 008 | 231223s2008 xx ||||| 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n0608.xml |
| 035 | |a (DE-627)NLM182322696 | ||
| 035 | |a (NLM)18780693 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Fernö, Mårten |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor |
| 246 | 3 | 3 | |a Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2008 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Haglund, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Bendahl, Pär-Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Olsson, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Rydén, Lisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 105(2008), 32-33 vom: 01. Aug., Seite 2181-4 |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2008 |g number:32-33 |g day:01 |g month:08 |g pages:2181-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2008 |e 32-33 |b 01 |c 08 |h 2181-4 | ||